Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06890884 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
A Phase 2 study of Lymphoma, Large B-Cell, Diffuse, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 594
- Enrollment target
- 20
- Study locations
NCT06890884: Recruiting Phase 2 study of Lymphoma, Large B-Cell, Diffuse, sponsored by Merck Sharp & Dohme.
NCT06890884 is a Phase 2 study of Lymphoma, Large B-Cell, Diffuse that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 594 participants, above the 146-participant average among 10 other Lymphoma, Large B-Cell, Diffuse trials with a reported enrollment target (307% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06890884, a Phase 2 study of Lymphoma, Large B-Cell, Diffuse, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 594 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing. The goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.
Primary Outcome
CRR at EOT is defined as the percentage of participants who experience complete response (CR) per Lugano response criteria as assessed by blinded independent central review (BICR) at end of treatment. CR is complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. Participants with missing data or who discontinue treatment or study prior to reaching EOT will be considered non-responders an
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- BIOLOGICAL Rituximab
- BIOLOGICAL Zilovertamab vedotin
- BIOLOGICAL Rituximab Biosimilar
Study Locations (20)
Florida
- Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0130) - Boca Raton
- Baptist MD Anderson Cancer Center ( Site 0176) - Jacksonville
- Mount Sinai Cancer Center ( Site 0140) - Miami Beach
- Mid Florida Hematology and Oncology Center ( Site 0152) - Orange City
California
- Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0135) - Burbank
- Bass Medical Group ( Site 0123) - Walnut Creek
Colorado
- Rocky Mountain Cancer Centers (RMCC) ( Site 8001) - Aurora
- Colorado West Healthcare System-Grand Valley Oncology ( Site 0165) - Grand Junction
Illinois
- University of Chicago Medical Center ( Site 0126) - Chicago
- Illinois Cancer Care ( Site 7005) - Peoria
Iowa
- University of Iowa-Holden Comprehensive Cancer Center ( Site 0139) - Iowa City
- Mission Blood & Cancer Care ( Site 0114) - Waukee
Kentucky
- Saint Elizabeth Medical Center Edgewood ( Site 0141) - Edgewood
- Baptist Health Hardin ( Site 0154) - Elizabethtown
Alabama
- Infirmary Cancer Care ( Site 0157) - Mobile
Arizona
- Palo Verde Cancer Specialists ( Site 0105) - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 594 participants |
| Start Date | 2025-04-11 |
| Est. Completion | 2032-12-16 |
| Phase | Phase 2 |
What NCT06890884 shows while recruiting
NCT06890884 is an interventional study that assigns participants to a tested intervention. The registered 594 participants enrollment target is mid-sized for trials with a published cap, above the 146-participant average among 10 other Lymphoma, Large B-Cell, Diffuse trials with a reported enrollment target (307% higher).
The record links to 1 condition, with Lymphoma, Large B-Cell, Diffuse appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT06890884 names 20 study sites across 12 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06890884 about?
NCT06890884 is a clinical study titled "A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)". Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing. The goal of this study is to learn if more people wh...
What is the current status of trial NCT06890884?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 594 participants. The study started on 2025-04-11. Estimated completion is 2032-12-16.
What conditions does trial NCT06890884 study?
This clinical trial studies the following conditions: Lymphoma, Large B-Cell, Diffuse.
What interventions are being tested in trial NCT06890884?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Rituximab (BIOLOGICAL), Zilovertamab vedotin (BIOLOGICAL), Rituximab Biosimilar (BIOLOGICAL).
Who is sponsoring clinical trial NCT06890884?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06890884 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Large B-Cell, Diffuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06890884's enrollment target sits among peer trials
594 1st of 10 higher than 10 of 10 other Lymphoma, Large B-Cell, Diffuse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma, Large B-Cell, Diffuse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
-
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
COMPLETED · Phase 2
-
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
COMPLETED · Phase 2
-
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04701684 · 594 participants · NA
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
- NCT05491213 · 594 participants · NA
TELESCOPE- TELEhealth Shared Decision-making COaching
- NCT05867420 · 594 participants · Phase 1
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
- NCT06892548 · 594 participants · Phase 1
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI